Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Core Insights - Structure Therapeutics Inc. is presenting two late-breaking posters at the American Diabetes Association 85 Scientific Sessions, focusing on their oral small molecule therapeutics for metabolic diseases [1][2] Group 1: Product Development - ACCG-2671 is positioned as a frontrunner oral small molecule targeting obesity, expected to enter clinical development by the end of 2025, with promising preclinical data showing significant weight-loss effects [2][3] - The combination therapy of ACCG-2671 with semaglutide resulted in superior weight loss compared to monotherapy in diet-induced obese rats [3] - GSBR-5595, another small molecule GLP-1 receptor agonist, demonstrated significant improvements in motor coordination and an increase in dopaminergic neurons in a Parkinson's disease mouse model [4][7] Group 2: Company Overview - Structure Therapeutics is focused on developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions, utilizing a structure-based drug discovery platform [5] - The company has established a robust pipeline targeting GPCRs, aiming to create scalable and cost-effective treatments that are accessible to a broader patient population [5]